Praxis Precision Medicines Inc at TD Cowen Healthcare Conference Transcript
Thank you everyone for joining us for the firesidera fireside chat here at the TD Cow and Healthcare Conference. I'm covering analyst Ritu Bharal and joining us from.
Joining us from practice, we have Marcio. I don't have apparently I would come back, Marcio.
We have to my right, Tim Kelly, CFO, and Marcio Souza, CEO, who I'm sure you guys all know. Let's start right away. I know, right? Well, thank you guys for doing the breakfast this morning. We were really able to get into some of the nitty gritty. And we'll just keep riffing off of some of that, but let's start sort of higher level. It's going to be an enormously busy year for you guys. We'll start with the main driver is Ulixa for essential tremor, but you have NDA submitted both for that andralutrigine. You filed, as we started off this morning at breakfast, you filed and will not be requesting priority review. So you are anticipating for Ulixa.
A standard review process. Can you remind us of the factors that guided this decision and, especially addressing keeping your relationship with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
